Company / Return on Equity (ROE)
ORAMED PHARMACEUTICALS INC. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-13.1%
FY2025
5-year range
-22.3% / 3.5%
FY2021-FY2025
Trend
-476.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ORAMED PHARMACEUTICALS INC. reports negative total equity of -13.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-13.1% in FY2025 with a 5-year CAGR of +60.9%.
Improved from -22.3% to -13.1% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +2.0pp
- 5-Year Change
- +60.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 476.7% year-over-year.
- Peak return on equity (roe) was recorded in FY2024.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -13.1% | -476.7% |
| FY2024 | 3.5% | +115.6% |
| FY2023 | -22.3% | -47.4% |
| FY2022 | -15.1% | -52.3% |
| FY2021 | -9.9% | +86.6% |
| FY2020 | -74.0% | -119.8% |
| FY2019 | -33.7% | +19.5% |
| FY2018 | -41.9% | -43.7% |
| FY2017 | -29.1% | -6.4% |
| FY2016 | -27.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026